---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-907"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-907. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 1 further heading. 10 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-907"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-907

<a id="heading-3.1.13"></a>

## 3.1.13 ABX464-907

<a id="heading-3.1.13.1"></a>

### 3.1.13.1 Objective

<a id="topic-3.1.13.1-1"></a>

#### Purpose stated in the EU register title

> “A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="heading-3.1.13.2"></a>

### 3.1.13.2 Location and Study Date

<a id="topic-3.1.13.2-1"></a>

#### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-907” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/09/2024” |
| End of trial | “End of trial 14/10/2025” |

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="topic-3.1.13.2-2"></a>

#### Trial site

> “CRS Clinical Research Services Management GmbH”
> “Clinical Unit, Lornsenstrasse 7, Brunswik, Kiel”

Source: [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)

<a id="heading-3.1.13.3"></a>

### 3.1.13.3 Study Design

<a id="topic-3.1.13.3-1"></a>

#### Phase 1 multiple-dose design with matched controls

> “Trial Phase Human Pharmacology (Phase I)- Other”
> “multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="topic-3.1.13.3-2"></a>

#### Additional Phase 1 trials described in the Form 20-F

> “Furthermore, additional Phase 1 clinical trials to support NDA submission are ongoing.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.13.4"></a>

### 3.1.13.4 Eligibility Criteria

<a id="topic-3.1.13.4-1"></a>

#### Participant type and age in the EU register

| Field | Register entry |
| --- | --- |
| Participants type | “Participants type Healthy volunteers, Patients” |
| Age range | “Age range 18-64 years, 65+ years” |

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="heading-3.1.13.5"></a>

### 3.1.13.5 Treatment

<a id="topic-3.1.13.5-1"></a>

#### Multiple oral doses of obefazimod

> “multiple oral doses of obefazimod”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="heading-3.1.13.6"></a>

### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

#### 3.1.13.6.1 Rationale for Using Obefazimod Pharmacokinetics in Renal Impairment as the Study Endpoint

No evidence found.

<a id="heading-3.1.13.7"></a>

### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

#### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.13.7.1-1"></a>

##### Planned participants in the EU register

> “Germany: Ended. Planned participants: 48”

Source: [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)

<a id="heading-3.1.13.7.2"></a>

#### 3.1.13.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.13.8"></a>

### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

#### 3.1.13.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.13.8.2"></a>

#### 3.1.13.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.13.8.3"></a>

#### 3.1.13.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.13.8.4"></a>

#### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.13.8.5"></a>

#### 3.1.13.8.5 Safety Results

No evidence found.

<a id="heading-3.1.13.9"></a>

### 3.1.13.9 Study Limitations

<a id="topic-3.1.13.9-1"></a>

#### Summary

ABX464-907 has only an EU register record. The register gives the title, the dates (9 September 2024 to 14 October 2025), one site in Germany, and 48 planned participants, who include patients and healthy volunteers aged 18 years or older. The Form 20-F does not name this trial among the completed Phase 1 trials. The categories of renal impairment, the dose, the number per group, the inclusion of participants on dialysis, and the endpoints are not public, and the summary of results is deferred until 14 April 2028. No exposure or safety result is available to inform dosing in renal impairment.

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00); [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.13.9-2"></a>

#### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 14 Apr 2028 (EMA/263067/2023).”

Source: [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
